GSK (NYSE:GSK) Issues FY 2024 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.710-1.740 for the period, compared to the consensus EPS estimate of 4.060. The company issued revenue guidance of $40.9 billion-$41.7 billion, compared to the consensus revenue estimate of $41.5 billion.

GSK Stock Performance

Shares of GSK traded up $0.11 during mid-day trading on Friday, hitting $36.87. The company’s stock had a trading volume of 6,876,973 shares, compared to its average volume of 3,858,042. GSK has a one year low of $33.67 and a one year high of $45.92. The stock’s 50-day moving average is $40.78 and its two-hundred day moving average is $41.05. The firm has a market capitalization of $76.41 billion, a PE ratio of 24.10, a price-to-earnings-growth ratio of 1.23 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. GSK had a net margin of 7.97% and a return on equity of 51.23%. As a group, sell-side analysts anticipate that GSK will post 4.08 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.26%. GSK’s dividend payout ratio (DPR) is 98.70%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several analyst reports. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, one has assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.00.

Insider Activity

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.